{"disease":{"id":"relapsed-adult-aml","name":"relapsed adult aml"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05193448","title":"A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCE","phase":"","overall_status":"COMPLETED","enrollment_count":177,"lead_sponsor_name":"French Innovative Leukemia Organisation","has_results":false},{"nct_id":"NCT06613217","title":"Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"Pacylex Pharmaceuticals","has_results":false},{"nct_id":"NCT04139434","title":"Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Newave Pharmaceutical Inc","has_results":false},{"nct_id":"NCT05305859","title":"Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"The First Affiliated Hospital of Xiamen University","has_results":false},{"nct_id":"NCT04722952","title":"PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT04310592","title":"Natural Killer Cell (CYNK-001) Infusions in Adults with AML","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":27,"lead_sponsor_name":"Celularity Incorporated","has_results":false},{"nct_id":"NCT06307054","title":"CLL-1 CAR-NK Cells for Relapsed/Refractory AML","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT05029141","title":"New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":21,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT03091933","title":"Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Ciusss de L'Est de l'Île de Montréal","has_results":false},{"nct_id":"NCT03848754","title":"Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Medical College of Wisconsin","has_results":false},{"nct_id":"NCT06649227","title":"Study Investigating the Safety of CD19 CAR-T Cells in Relapsed/Refractory AML Expressing CD19","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":5,"lead_sponsor_name":"University Hospital, Lille","has_results":false},{"nct_id":"NCT06586099","title":"Tislelizumab with Azacitidine in the Treatment of R/R AML","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT03245424","title":"Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Agios Pharmaceuticals, Inc.","has_results":false}],"total":13},"guidelines":[],"source":"Drug Landscape verified database"}